At a glance
ClinicalIndex Comparison RecordN/ACompleted· 116 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·observational·Posted Aug 9, 2021·Updated Dec 18, 2024
In Brief
An observational study for Relapsing-Remitting Multiple Sclerosis. Completed, enrolled 116 participants across 8 sites.
Detailed Summary
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-Remitting Multiple Sclerosis
CountriesUnited Kingdom
CollaboratorsMerck Serono Limited, UK
Timeline
N/ACompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2021
Primary CompletionSep 2023
TodayJul 2026
First PostedAug 9, 2021
Enrollment StartAug 11, 2021
Primary CompletionSep 14, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.9 years ago